A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis

Michael Luchi, David C. Morrison, Steven Opal, Ken Y Yoneda, Gus Slotman, Henry Chambers, Harold Wiesenfeld, Jon Lemke, John L. Ryan, David Horn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Evidence from in vitro experiments and animal and human studies indicate that antibiotic therapy may induce the release of endotoxin from the outer membrane of Gram-negative bacteria. Antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2) - such as imipenem - are associated with little release of endotoxin, while antibiotics that preferentially bind to PBP-3 - such as ceftazidime - are associated with far greater release of endotoxin. We conducted a randomized, multicenter, double-blind study comparing imipenem to ceftazidime in patients with urinary tract infections caused by Gram-negative bacilli associated with signs and symptoms of systemic inflammation. A total of 33 patients were randomized to receive either imipenem (n = 14) or ceftazidime (n = 19) for initial treatment for urosepsis. No differences in plasma endotoxin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or urine endotoxin, IL-6 or IL-8 levels were found between the two treatment groups within the first 8 h after antibiotic administration. We conclude that, if differences exist with respect to endotoxin release by these two antimicrobial agents, these differences are not readily demonstrable in this clinical study with carefully defined patients with Gram-negative urinary tract infections.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalJournal of Endotoxin Research
Volume6
Issue number1
StatePublished - 2000

Fingerprint

Ceftazidime
Imipenem
Endotoxins
Cytokines
Anti-Bacterial Agents
Urinary Tract Infections
Interleukin-6
Penicillin-Binding Proteins
Bacilli
Anti-Infective Agents
Gram-Negative Bacteria
Interleukin-8
Double-Blind Method
Bacillus
Signs and Symptoms
Bacteria
Animals
Therapeutics
Tumor Necrosis Factor-alpha
Urine

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Toxicology

Cite this

A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis. / Luchi, Michael; Morrison, David C.; Opal, Steven; Yoneda, Ken Y; Slotman, Gus; Chambers, Henry; Wiesenfeld, Harold; Lemke, Jon; Ryan, John L.; Horn, David.

In: Journal of Endotoxin Research, Vol. 6, No. 1, 2000, p. 25-31.

Research output: Contribution to journalArticle

Luchi, M, Morrison, DC, Opal, S, Yoneda, KY, Slotman, G, Chambers, H, Wiesenfeld, H, Lemke, J, Ryan, JL & Horn, D 2000, 'A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis', Journal of Endotoxin Research, vol. 6, no. 1, pp. 25-31.
Luchi, Michael ; Morrison, David C. ; Opal, Steven ; Yoneda, Ken Y ; Slotman, Gus ; Chambers, Henry ; Wiesenfeld, Harold ; Lemke, Jon ; Ryan, John L. ; Horn, David. / A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis. In: Journal of Endotoxin Research. 2000 ; Vol. 6, No. 1. pp. 25-31.
@article{094076d5e0e049659e9f7e93cf481091,
title = "A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis",
abstract = "Evidence from in vitro experiments and animal and human studies indicate that antibiotic therapy may induce the release of endotoxin from the outer membrane of Gram-negative bacteria. Antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2) - such as imipenem - are associated with little release of endotoxin, while antibiotics that preferentially bind to PBP-3 - such as ceftazidime - are associated with far greater release of endotoxin. We conducted a randomized, multicenter, double-blind study comparing imipenem to ceftazidime in patients with urinary tract infections caused by Gram-negative bacilli associated with signs and symptoms of systemic inflammation. A total of 33 patients were randomized to receive either imipenem (n = 14) or ceftazidime (n = 19) for initial treatment for urosepsis. No differences in plasma endotoxin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or urine endotoxin, IL-6 or IL-8 levels were found between the two treatment groups within the first 8 h after antibiotic administration. We conclude that, if differences exist with respect to endotoxin release by these two antimicrobial agents, these differences are not readily demonstrable in this clinical study with carefully defined patients with Gram-negative urinary tract infections.",
author = "Michael Luchi and Morrison, {David C.} and Steven Opal and Yoneda, {Ken Y} and Gus Slotman and Henry Chambers and Harold Wiesenfeld and Jon Lemke and Ryan, {John L.} and David Horn",
year = "2000",
language = "English (US)",
volume = "6",
pages = "25--31",
journal = "Innate Immunity",
issn = "1753-4259",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis

AU - Luchi, Michael

AU - Morrison, David C.

AU - Opal, Steven

AU - Yoneda, Ken Y

AU - Slotman, Gus

AU - Chambers, Henry

AU - Wiesenfeld, Harold

AU - Lemke, Jon

AU - Ryan, John L.

AU - Horn, David

PY - 2000

Y1 - 2000

N2 - Evidence from in vitro experiments and animal and human studies indicate that antibiotic therapy may induce the release of endotoxin from the outer membrane of Gram-negative bacteria. Antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2) - such as imipenem - are associated with little release of endotoxin, while antibiotics that preferentially bind to PBP-3 - such as ceftazidime - are associated with far greater release of endotoxin. We conducted a randomized, multicenter, double-blind study comparing imipenem to ceftazidime in patients with urinary tract infections caused by Gram-negative bacilli associated with signs and symptoms of systemic inflammation. A total of 33 patients were randomized to receive either imipenem (n = 14) or ceftazidime (n = 19) for initial treatment for urosepsis. No differences in plasma endotoxin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or urine endotoxin, IL-6 or IL-8 levels were found between the two treatment groups within the first 8 h after antibiotic administration. We conclude that, if differences exist with respect to endotoxin release by these two antimicrobial agents, these differences are not readily demonstrable in this clinical study with carefully defined patients with Gram-negative urinary tract infections.

AB - Evidence from in vitro experiments and animal and human studies indicate that antibiotic therapy may induce the release of endotoxin from the outer membrane of Gram-negative bacteria. Antibiotics that bind preferentially to penicillin-binding protein-2 (PBP-2) - such as imipenem - are associated with little release of endotoxin, while antibiotics that preferentially bind to PBP-3 - such as ceftazidime - are associated with far greater release of endotoxin. We conducted a randomized, multicenter, double-blind study comparing imipenem to ceftazidime in patients with urinary tract infections caused by Gram-negative bacilli associated with signs and symptoms of systemic inflammation. A total of 33 patients were randomized to receive either imipenem (n = 14) or ceftazidime (n = 19) for initial treatment for urosepsis. No differences in plasma endotoxin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) or urine endotoxin, IL-6 or IL-8 levels were found between the two treatment groups within the first 8 h after antibiotic administration. We conclude that, if differences exist with respect to endotoxin release by these two antimicrobial agents, these differences are not readily demonstrable in this clinical study with carefully defined patients with Gram-negative urinary tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0033949218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033949218&partnerID=8YFLogxK

M3 - Article

C2 - 11061029

AN - SCOPUS:0033949218

VL - 6

SP - 25

EP - 31

JO - Innate Immunity

JF - Innate Immunity

SN - 1753-4259

IS - 1

ER -